传Moderna新冠病毒疫苗每疗程定价50至60美元
《金融时报》引述消息人士报道,美国生物科技公司Moderna计划将新冠病毒疫苗的定价定为每疗程50至60美元,价格比辉瑞及BioNTech联合研发的另一种疫苗至少高出11美元。
据悉,Moderna的建议价格将适用於美国及其他高收入国家,但尚未确定最终的价格。不过业内分析人士称,辉瑞及BioNTech与美国政府达成的20亿美元协议,可能会迫使其他制造商定下类似的价格。
此前辉瑞、 Moderna及默克皆表示,计划在有利润的方式下出售疫苗,而包括强生在内的一些药厂则宣布在非牟利的基础下为疫苗定价。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.